|
1
|
Kilfoy BA, Zheng T, Holford TR, Han X,
Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, et al:
International patterns and trends in thyroid cancer incidence,
1973–2002. Cancer Causes Control. 20:525–531. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cai X, Zhao Z, Dong J, Lv Q, Yun B, Liu J,
Shen Y, Kang J and Li J: Circular RNA circBACH2 plays a role in
papillary thyroid carcinoma by sponging miR-139-5p and regulating
LMO4 expression. Cell Death Dis. 10:1842019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heidari Z, Mohammadpour-Gharehbagh A,
Eskandari M, Harati-Sadegh M and Salimi S: Genetic polymorphisms of
miRNA let7a-2 and pri-mir-34b/c are associated with an increased
risk of papillary thyroid carcinoma and clinical/pathological
features. J Cell Biochem. Dec 14–2018.(Epub ahead of print). doi:
10.1002/jcb.28152.
|
|
4
|
La Vecchia C, Malvezzi M, Bosetti C,
Garavello W, Bertuccio P, Levi F and Negri E: Thyroid cancer
mortality and incidence: A global overview. Int J Cancer.
136:2187–2195. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akslen LA, Haldorsen T, Thoresen SO and
Glattre E: Incidence pattern of thyroid cancer in Norway: Influence
of birth cohort and time period. Int J Cancer. 53:183–187. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colonna M, Grosclaude P, Remontet L,
Schvartz C, Mace-Lesech J, Velten M, Guizard A, Tretarre B, Buemi
AV, Arveux P and Esteve J: Incidence of thyroid cancer in adults
recorded by French cancer registries (1978–1997). Eur J Cancer.
38:1762–1768. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
dos Santos Silva I and Swerdlow AJ:
Thyroid cancer epidemiology in England and Wales: Time trends and
geographical distribution. Br J Cancer. 67:330–340. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montanaro F, Pury P, Bordoni A and Lutz
JM; Swiss Cancer Registries Network, : Unexpected additional
increase in the incidence of thyroid cancer among a recent birth
cohort in Switzerland. Eur J Cancer Prev. 15:178–186. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pettersson B, Adami HO, Wilander E and
Coleman MP: Trends in thyroid cancer incidence in Sweden,
1958–1981, by histopathologic type. Int J Cancer. 48:28–33. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ferlay J, Colombet M and Bray F: Cancer
incidence in five continents, CI5plus: IARC CancerBase No. 9
[Internet]. Lyon, France: International Agency for Research on
Cancer; 2018
|
|
11
|
Pathak KA, Leslie WD, Klonisch TC and
Nason RW: The changing face of thyroid cancer in a population-based
cohort. Cancer Med. 2:537–544. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jayarangaiah A, Sidhu G, Brown J,
Barrett-Campbell O, Bahtiyar G, Youssef I, Arora S, Skwiersky S and
McFarlane SI: Therapeutic options for advanced thyroid cancer. Int
J Clin Endocrinol Metab. 5:26–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rahmani N, Abbas Hashemi S, Fazli M and
Raisian M: Clinical management and outcomes of papillary,
follicular and medullary thyroid cancer surgery. Med Glas (Zenica).
10:164–167. 2013.PubMed/NCBI
|
|
14
|
Lin JD, Chao TC, Huang MJ, Weng HF and
Tzen KY: Use of radioactive iodine for thyroid remnant ablation in
well-differentiated thyroid carcinoma to replace thyroid
reoperation. Am J Clin Oncol. 21:77–81. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gottlieb JA and Hill CS Jr: Chemotherapy
of thyroid cancer with adriamycin. Experience with 30 patients. N
Engl J Med. 290:193–197. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Long MY, Chen JW, Zhu Y, Luo DY, Lin SJ,
Peng XZ, Tan LP and Li HH: Comprehensive circular RNA profiling
reveals the regulatory role of circRNA_0007694 in papillary thyroid
carcinoma. Am J Transl Res. 12:1362–1378. 2020.PubMed/NCBI
|
|
17
|
Dong S, Xie XJ, Xia Q and Wu YJ:
Indicators of multifocality in papillary thyroid carcinoma
concurrent with Hashimoto's thyroiditis. Am J Cancer Res.
9:1786–1795. 2019.PubMed/NCBI
|
|
18
|
Xing M, Westra WH, Tufano RP, Cohen Y,
Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et
al: BRAF mutation predicts a poorer clinical prognosis for
papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Basolo F, Torregrossa L, Giannini R,
Miccoli M, Lupi C, Sensi E, Berti P, Elisei R, Vitti P, Baggiani A
and Miccoli P: Correlation between the BRAF V600E mutation and
tumor invasiveness in papillary thyroid carcinomas smaller than 20
millimeters: Analysis of 1060 cases. J Clin Endocrinol Metab.
95:4197–4205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elisei R, Viola D, Torregrossa L, Giannini
R, Romei C, Ugolini C, Molinaro E, Agate L, Biagini A, Lupi C, et
al: The BRAF(V600E) mutation is an independent, poor prognostic
factor for the outcome of patients with low-risk intrathyroid
papillary thyroid carcinoma: Single-institution results from a
large cohort study. J Clin Endocrinol Metab. 97:4390–4398. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Markopoulos GS, Roupakia E, Tokamani M,
Chavdoula E, Hatziapostolou M, Polytarchou C, Marcu KB,
Papavassiliou AG, Sandaltzopoulos R and Kolettas E: A step-by-step
microRNA guide to cancer development and metastasis. Cell Oncol
(Dordr). 40:303–339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shukla GC and Gupta S: Hallmarks of
cancer-focus on RNA metabolism and regulatory noncoding RNAs.
Cancer Lett. 420:208–209. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Calin GA, Dumitru CD, Shimizu M, Bichi R,
Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, et al:
Frequent deletions and down-regulation of micro-RNA genes miR15 and
miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci
USA. 99:15524–15529. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fabbri M, Garzon R, Cimmino A, Liu Z,
Zanesi N, Callegari E, Liu S, Alder H, Costinean S,
Fernandez-Cymering C, et al: MicroRNA-29 family reverts aberrant
methylation in lung cancer by targeting DNA methyltransferases 3A
and 3B. Proc Natl Acad Sci USA. 104:15805–15810. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ferreira AF, Moura LG, Tojal I, Ambrósio
L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT,
Kashima S and Castro FA: ApoptomiRs expression modulated by BCR-ABL
is linked to CML progression and imatinib resistance. Blood Cells
Mol Dis. 53:47–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scholl V, Hassan R and Zalcberg IR:
miRNA-451: A putative predictor marker of Imatinib therapy response
in chronic myeloid leukemia. Leuk Res. 36:119–121. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Muhammad N, Bhattacharya S, Steele R and
Ray RB: Anti-miR-203 suppresses ER-positive breast cancer growth
and stemness by targeting SOCS3. Oncotarget. 7:58595–58605. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cardona-Monzonís A, García-Giménez JL,
Mena-Mollá S, Pareja-Galeano H, de la Guía-Galipienso F, Lippi G,
Pallardó FV and Sanchis-Gomar F: Non-coding RNAs and coronary
artery disease. Adv Exp Med Biol. 1229:273–285. 2020. View Article : Google Scholar
|
|
30
|
Zhang Y, Xue W, Li X, Zhang J, Chen S,
Zhang JL, Yang L and Chen LL: The biogenesis of nascent circular
RNAs. Cell Rep. 15:611–624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kristensen LS, Andersen MS, Stagsted LVW,
Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and
characterization of circular RNAs. Nat Rev Genet. 20:675–691. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shan C, Zhang Y, Hao X, Gao J, Chen X and
Wang K: Biogenesis, functions and clinical significance of circRNAs
in gastric cancer. Mol Cancer. 18:1362019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kristensen LS, Hansen TB, Venø MT and
Kjems J: Circular RNAs in cancer: Opportunities and challenges in
the field. Oncogene. 37:555–565. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mingyan L, Yujie L and Min Y: CircRNA
ZNF609 knockdown suppresses cell growth via modulating miR-188/ELF2
axis in nasopharyngeal carcinoma. Onco Targets Ther. 13:2399–2409.
2020. View Article : Google Scholar
|
|
36
|
Liang HF, Zhang XZ, Liu BG, Jia GT and Li
WL: Circular RNA circ-ABCB10 promotes breast cancer proliferation
and progression through sponging miR-1271. Am J Cancer Res.
7:1566–1576. 2017.PubMed/NCBI
|
|
37
|
Zhang SJ, Ma J, Wu JC, Hao ZZ, Zhang YA
and Zhang YJ: Circular RNA circCRIM1 suppresses lung adenocarcinoma
cell migration, invasion, EMT, and glycolysis through regulating
miR-125b-5p/BTG2 axis. Eur Rev Med Pharmacol Sci. 24:3761–3774.
2020.PubMed/NCBI
|
|
38
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Garcia DM, Baek D, Shin C, Bell GW,
Grimson A and Bartel DP: Weak seed-pairing stability and high
target-site abundance decrease the proficiency of lsy-6 and other
microRNAs. Nat Struct Mol Biol. 18:1139–1146. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Enright AJ, John B, Gaul U, Tuschl T,
Sander C and Marks DS: MicroRNA targets in Drosophila. Genome Biol.
5:R12003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Salmena L, Poliseno L, Tay Y, Kats L and
Pandolfi PP: A ceRNA hypothesis: The rosetta stone of a hidden RNA
language? Cell. 146:353–358. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42((Database Issue)): D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Zhang Q, Miao S, Han X, Li C, Zhang M, Cui
K, Xiong T, Chen Z, Wang C and Xu H: MicroRNA-3619-5p suppresses
bladder carcinoma progression by directly targeting β-catenin and
CDK2 and activating p21. Cell Death Dis. 9:9602018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Li Y, Fan H, Sun J, Ni M, Zhang L, Chen C,
Hong X, Fang F, Zhang W and Ma P: Circular RNA expression profile
of Alzheimer's disease and its clinical significance as biomarkers
for the disease risk and progression. Int J Biochem Cell Biol.
123:1057472020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wen G, Zhou T and Gu W: The potential of
using blood circular RNA as liquid biopsy biomarker for human
diseases. Protein Cell. Nov 1–2020.(Epub ahead of print). doi:
10.1007/s13238-020-00799-3. View Article : Google Scholar
|
|
47
|
Rahman ST, McLeod DSA, Pandeya N, Neale
RE, Bain CJ, Baade P, Youl PH and Jordan SJ: Understanding pathways
to the diagnosis of thyroid cancer: Are there ways we can reduce
over-diagnosis? Thyroid. 29:341–348. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Krajewska J, Kukulska A,
Oczko-Wojciechowska M, Kotecka-Blicharz A, Drosik-Rutowicz K,
Haras-Gil M, Jarzab B and Handkiewicz-Junak D: Early diagnosis of
low-risk papillary thyroid cancer results rather in overtreatment
than a better survival. Front Endocrinol (Lausanne). 11:5714212020.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bruland O, Fluge Ø, Akslen LA, Eiken HG,
Lillehaug JR, Varhaug JE and Knappskog PM: Inverse correlation
between PDGFC expression and lymphocyte infiltration in human
papillary thyroid carcinomas. BMC Cancer. 9:4252009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Stuchi LP, Castanhole-Nunes MMU,
Maniezzo-Stuchi N, Biselli-Chicote PM, Henrique T, Padovani Neto
JA, de-Santi Neto D, Girol AP, Pavarino EC and Goloni-Bertollo EM:
VEGFA and NFE2L2 gene expression and regulation by MicroRNAs in
thyroid papillary cancer and colloid goiter. Genes (Basel).
11:9542020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lin X, Wu JF, Wang DM, Zhang J, Zhang WJ
and Xue G: The correlation and role analysis of KCNK2/4/5/15 in
human papillary thyroid carcinoma microenvironment. J Cancer.
11:5162–5176. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gugnoni M, Manicardi V, Torricelli F,
Sauta E, Bellazzi R, Manzotti G, Vitale E, de Biase D, Piana S and
Ciarrocchi A: Linc00941 is a novel transforming growth factor β
target that primes papillary thyroid cancer metastatic behavior by
regulating the expression of cadherin 6. Thyroid. 31:247–263. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Peng N, Shi L, Zhang Q, Hu Y, Wang N and
Ye H: Microarray profiling of circular RNAs in human papillary
thyroid carcinoma. PLoS One. 12:e01702872017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ren H, Liu Z, Liu S, Zhou X, Wang H, Xu J,
Wang D and Yuan G: Profile and clinical implication of circular
RNAs in human papillary thyroid carcinoma. PeerJ. 6:e53632018.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Qi X, Zhang DH, Wu N, Xiao JH, Wang X and
Ma W: ceRNA in cancer: Possible functions and clinical
implications. J Med Genet. 52:710–718. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Su H, Tao T, Yang Z, Kang X, Zhang X, Kang
D, Wu S and Li C: Circular RNA cTFRC acts as the sponge of
MicroRNA-107 to promote bladder carcinoma progression. Mol Cancer.
18:272019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tang YQ, Jaganath IB, Manikam R and
Sekaran SD: Inhibition of MAPKs, Myc/Max, NFκB, and hypoxia
pathways by Phyllanthus prevents proliferation, metastasis
and angiogenesis in human melanoma (MeWo) cancer cell line. Int J
Med Sci. 11:564–577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pacifico F and Leonardi A: Role of
NF-kappaB in thyroid cancer. Mol Cell Endocrinol. 321:29–35. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Beinke S and Ley SC: Functions of
NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J.
382:393–409. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kucharczak J, Simmons MJ, Fan Y and
Gélinas C: To be, or not to be: NF-kappaB is the answer--role of
Rel/NF-kappaB in the regulation of apoptosis. Oncogene.
22:8961–8982. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Fu X, Fang J, Lian M, Zhong Q, Ma H, Feng
L, Wang R and Wang H: Identification of microRNAs associated with
medullary thyroid carcinoma by bioinformatics analyses. Mol Med
Rep. 15:4266–4272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Chen Z, Yan B and Van Waes C: The role of
the NF-kappaB transcriptome and proteome as biomarkers in human
head and neck squamous cell carcinomas. Biomark Med. 2:409–426.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Durairajan S, Jebaraj Walter CE, Samuel
MD, Palani D, G DJD, C GPD, Pasupati S and Johnson T: Differential
expression of NF-κB heterodimer RelA/p50 in human urothelial
carcinoma. PeerJ. 6:e55632018. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Qadir J, Riaz SK, Sahar NE, Aman D, Khan
MJ and Malik MFA: Transcriptional elucidation of tumor necrosis
factor-α-mediated nuclear factor-κB1 activation in breast cancer
cohort of Pakistan. J Cancer Res Ther. 16:1443–1448.
2020.PubMed/NCBI
|
|
66
|
Honma M, Kato N, Hashimoto M, Takahashi H,
Ishida-Yamamoto A and Iizuka H: Subungual keratoacanthoma: Analysis
of cell proliferation and copy number variation of oncogenes
compared with periungual squamous cell carcinoma. Clin Exp
Dermatol. 36:57–62. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Li S, Wang C, Yu X, Wu H, Hu J, Wang S and
Ye Z: miR-3619-5p inhibits prostate cancer cell growth by
activating CDKN1A expression. Oncol Rep. 37:241–248. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Zhang M, Luo H and Hui L: miR-3619-5p
hampers proliferation and cisplatin resistance in cutaneous
squamous-cell carcinoma via KPNA4. Biochem Biophys Res Commun.
513:419–425. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Hao P, Yue F, Xian X, Ren Q, Cui H and
Wang Y: Inhibiting effect of MicroRNA-3619-5p/PSMD10 axis on liver
cancer cell growth in vivo and in vitro. Life Sci. 254:1176322020.
View Article : Google Scholar : PubMed/NCBI
|
